Molecure S.A.

Equities

MOC

PLONCTH00011

Biotechnology & Medical Research

Market Closed - Warsaw S.E. Other stock markets 16:55:41 03/06/2024 BST			5-day change	1st Jan Change
15.26 ^PLN	+2.28%		+0.53%	-21.74%

05-21	Molecure S.A. Receives Approval to Initiate A Phase II Clinical Trial for OATD-01 for the Treatment of Pulmonary Sarcoidosis in Selected Countries of the European Union and Norway	CI
05-17	Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 17, 2024 at 04:36 pm

Molecure S.A. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was PLN 0.028438 million compared to PLN 1.75 million a year ago. Net loss was PLN 7.03 million compared to PLN 5.95 million a year ago.

Latest news about Molecure S.A.

Molecure S.A. Receives Approval to Initiate A Phase II Clinical Trial for OATD-01 for the Treatment of Pulmonary Sarcoidosis in Selected Countries of the European Union and Norway	05-21	CI
Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-17	CI
Molecure S.A. Announces First Patient in the OATD-01 Phase 2 KITE Study in Pulmonary Sarcoidosis	03-22	CI
Molecure S.A Announces No Grant of Permission to Conduct Phase II Clinical Trials for the OATD-01 Molecule I	01-16	CI
Molecure S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	30/10/23	CI
Molecure S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	28/09/23	CI
Poland's Molecure Gets US FDA Clearance for Mid-stage Trial of Potential Pulmonary Sarcoidosis Treatment	24/07/23	MT
Molecure S.A. Receives Clearance from the U.S. Food and Drug Administration on its Investigational New Drug Application to Conduct Phase II Clinical Testing of OATD-01	24/07/23	CI
Molecure S.A. announced that it has received PLN 49.968 million in funding	20/07/23	CI
Poland's Molecure Files Investigational New Drug Application with US FDA for Pulmonary Sarcoidosis Drug	23/06/23	MT
Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/04/23	CI
Molecure S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	29/03/23	CI
Poland's Molecure Doses First Patient in Cancer Treatment Trial	08/03/23	MT
Molecure Announces First Patient Dosed in Phase I Trial with Novel, First-In-Class Dual Arginase Inhibitor OATD-02 for the Treatment of Cancer	08/03/23	CI
Molecure S.A. Announces Management Changes	03/01/23	CI
Molecure S.A. to Begin Clinical Development of Novel Dual Arginase Inhibitor Oatd-02 for the Treatment of Cancer After Gaining Permission to Conduct First Clinical Trial in Poland	28/11/22	CI
Molecure S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	30/10/22	CI
Molecure S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	28/09/22	CI
Molecure S.A.(WSE:MOC) dropped from S&P Global BMI Index	19/09/22	CI
Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	28/04/22	CI
ONCOARENDI THERAPEUTICS S.A will Change its Name to Molecure S.A	04/04/22	CI
OncoArendi Therapeutics S.A. Announces A License Option Agreement with University of Michigan	11/03/22	CI
OncoArendi Therapeutics S.A. Announces Board Appointments	31/01/22	CI
OncoArendi Therapeutics S.A Appoints Samson Fung as Chief Medical Officer	27/01/22	CI
OncoArendi Therapeutics S.A. Announces Board Changes	14/01/22	CI

Chart Molecure S.A.

Duration

Period

More charts

Company Profile

Oncoarendi Therapeutics SA is a Poland-based biopharmaceutical company . The Company is dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The Company's business model is focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations in specific disease areas. The Company has a platform of 3 distinct small molecule programs targeting chitinases hydrolytic enzymes with potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need. Additionally, it has initiated a program focused on development of small molecule immune modulators to stop the ability of tumors to escape immune surveillance.

Sector

Biotechnology & Medical Research

Calendar

26/09/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Molecure S.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.92 PLN

Average target price

29.8 PLN

Spread / Average Target

+99.73%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MOLECURE S.A.	-21.74%	63.74M
VERTEX PHARMACEUTICALS INCORPORATED	+15.13%	118B
REGENERON PHARMACEUTICALS, INC.	+13.08%	106B
BIONTECH SE	-2.83%	24.28B
ARGENX SE	+1.14%	21.96B
GENMAB A/S	-9.35%	18.16B
WUXI APPTEC CO., LTD.	-42.28%	16.37B
BEIGENE, LTD.	-16.87%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+4.84%	13.63B
SAREPTA THERAPEUTICS, INC.	+28.67%	12.27B

Bio Therapeutic Drugs